Targeted Nanorobots

FACTS identify 8 companies, with corporate entries including Angstrom Advanced Inc., Advance Technology Ltd and Imina Technologies. The data do not establish that each sells a targeted nanorobot product: company activity is not described in enough detail to confirm product portfolios or commercial readiness. Thermo Fisher Scientific also appears among organizations active in research approaches, but that alone does not establish a supplier role.

FACTS list 0 targeted nanorobots startups, so they do not support a ranking of promising startups for 2026. The listed activity is predominantly research-led, with 138 research organizations compared with 8 companies. For partner scouting, distinguish research groups and corporate mentions from companies with validated products, dedicated teams or disclosed commercial programs; those details are not provided here.

Harbin Institute of Technology leads the listed research organizations with 19 documents in the window, followed by 12579Southeast University with 11. Other active groups include Beijing Institute of Technology, the University of Chinese Academy of Sciences and Southern Medical University. Their work spans propulsion, magnetic control, DNA machines and applications such as drug delivery, tumor treatment and clot removal.

FACTS report $7,854,200 in funding across 8 grants since 2020. The data do not specify a complete breakdown by funder or individual award amount, so the total should be treated as the recorded grant funding rather than a full estimate of investment in the field. No funding rounds are listed.

FACTS list 0 funding rounds and $0 in round funding, so no latest targeted nanorobots rounds are recorded. Grant activity is separate: the data show 8 grants totaling $7,854,200 since 2020. This distinction matters for scouting because grant support indicates research funding, not necessarily company financing or a commercial investment.

Arizona Board Of Regents On Behalf Of Arizona State University and Multi-Scale Medical Robotics Center Limited each hold 1 listed patent. FACTS record 2 patents in the 24-month window and 7 patents overall. The available patent-holder data show one patent apiece for these organizations, so they are tied at the top of the listed holders.

FACTS record 0 clinical trials, while research accounts for 138 organizations and 117 publications in the last year. This points to a research-led field rather than established clinical deployment. Laboratory demonstrations and design studies are advancing, but translation still depends on showing safe navigation, predictable release, biological compatibility and reproducible performance in relevant settings.

Recent developments include Harbin Institute of Technology’s gold nanozyme-powered nanobots for tumor-specific delivery in August 2026 and a Capital Medical University study of potassium-scavenging nanorobots for glioblastoma in September 2026. An October 2026 publication examined cell-based micro/nanorobots as therapeutic specialists. Together, these examples point to responsive propulsion, combined functions and biohybrid carriers.

FACTS identify 6 approaches: magnetic actuation, acoustic actuation, chemical and enzymatic propulsion, light-driven systems, DNA molecular machines and biohybrid systems. Magnetic and acoustic methods use external energy or fields for guidance; chemical and enzymatic designs generate propulsion through reactions. DNA machines emphasize programmable structure and response, while biohybrids combine biological functions with engineered capabilities.

China leads the listed country activity with 453 documents, followed by the United States with 312 and India with 160. The United Kingdom and Germany are also active, with 135 and 108 documents respectively. These figures describe recorded document activity, not necessarily commercial leadership, clinical progress or the location of every research collaboration.